AbbVie Inc. (ABBV) experienced a significant pre-market plunge of 6.50% on Wednesday, a sharp reversal following the release of its fourth-quarter financial results.

Despite reporting adjusted earnings per share of $2.71, which exceeded analyst estimates of $2.65, and issuing 2026 profit guidance above Wall Street expectations, investor sentiment turned negative. Analysts noted that the quarterly revenue beat was primarily driven by stronger-than-expected sales of the legacy drug Humira, which continues to face steep declines due to biosimilar competition. Furthermore, sales of the newer immunology drug Rinvoq missed estimates.

The decline was exacerbated by reported weaknesses in other key business segments. The company's oncology portfolio revenue fell 1.5%, while its aesthetics business, including products like Botox Cosmetic, also saw a revenue decrease. An unfavorable impact of $0.71 per share related to acquired IPR&D and milestone expenses further weighed on results. Company executives also acknowledged that growth in the aesthetics market is expected to remain challenged in 2026.